GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Aquestive Therapeutics Inc (NAS:AQST) » Definitions » Quick Ratio

Aquestive Therapeutics (Aquestive Therapeutics) Quick Ratio : 1.87 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Aquestive Therapeutics Quick Ratio?

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. It is calculated as a company's Total Current Assets excludes Total Inventories divides by its Total Current Liabilities. Aquestive Therapeutics's quick ratio for the quarter that ended in Dec. 2023 was 1.87.

Aquestive Therapeutics has a quick ratio of 1.87. It generally indicates good short-term financial strength.

The historical rank and industry rank for Aquestive Therapeutics's Quick Ratio or its related term are showing as below:

AQST' s Quick Ratio Range Over the Past 10 Years
Min: 0.86   Med: 1.93   Max: 3.53
Current: 1.87

During the past 8 years, Aquestive Therapeutics's highest Quick Ratio was 3.53. The lowest was 0.86. And the median was 1.93.

AQST's Quick Ratio is ranked better than
63.13% of 1074 companies
in the Drug Manufacturers industry
Industry Median: 1.32 vs AQST: 1.87

Aquestive Therapeutics Quick Ratio Historical Data

The historical data trend for Aquestive Therapeutics's Quick Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aquestive Therapeutics Quick Ratio Chart

Aquestive Therapeutics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Quick Ratio
Get a 7-Day Free Trial 3.53 2.00 1.97 0.86 1.87

Aquestive Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Quick Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.86 0.91 0.88 1.47 1.87

Competitive Comparison of Aquestive Therapeutics's Quick Ratio

For the Drug Manufacturers - Specialty & Generic subindustry, Aquestive Therapeutics's Quick Ratio, along with its competitors' market caps and Quick Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aquestive Therapeutics's Quick Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Aquestive Therapeutics's Quick Ratio distribution charts can be found below:

* The bar in red indicates where Aquestive Therapeutics's Quick Ratio falls into.



Aquestive Therapeutics Quick Ratio Calculation

The quick ratio measures a company's ability to meet its short-term obligations with its most liquid assets. For this reason, the ratio excludes inventories from current assets.

Aquestive Therapeutics's Quick Ratio for the fiscal year that ended in Dec. 2023 is calculated as

Quick Ratio (A: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(40.966-6.769)/18.308
=1.87

Aquestive Therapeutics's Quick Ratio for the quarter that ended in Dec. 2023 is calculated as

Quick Ratio (Q: Dec. 2023 )=(Total Current Assets-Total Inventories)/Total Current Liabilities
=(40.966-6.769)/18.308
=1.87

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aquestive Therapeutics  (NAS:AQST) Quick Ratio Explanation

The quick ratio is more conservative than the Current Ratio because it excludes inventories from current assets. The ratio derives its name presumably from the fact that assets such as cash and marketable securities are quick sources of cash. Inventories generally take time to be converted into cash, and if they have to be sold quickly, the company may have to accept a lower price than book value of these inventories. As a result, they are justifiably excluded from assets that are ready sources of immediate cash.

In general, low or decreasing quick ratios generally suggest that a company is over-leveraged, struggling to maintain or grow sales, paying bills too quickly or collecting receivables too slowly. On the other hand, a high or increasing quick ratio generally indicates that a company is experiencing solid top-line growth, quickly converting receivables into cash, and easily able to cover its financial obligations. Such companies often have faster inventory turnover and cash conversion cycles.

The higher the quick ratio, the better the company's liquidity position.


Aquestive Therapeutics Quick Ratio Related Terms

Thank you for viewing the detailed overview of Aquestive Therapeutics's Quick Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aquestive Therapeutics (Aquestive Therapeutics) Business Description

Traded in Other Exchanges
N/A
Address
30 Technology Drive, Warren, NJ, USA, 07059
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Sympazan Oral Film, Suboxone Sublingual Film, Exservan Oral Film, and Zuplenz. The product pipeline includes Libervant Buccal Film, AQST-108, and AQST-305. The majority of its revenue comes from the United States.
Executives
Carl N Kraus officer: Chief Medical Officer C/O ACERAGEN, INC., 15 TW ALEXANDER DRIVE, DURHAM NC 27709
Stephen Wargacki officer: SVP, Research & Development C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Cassie Jung officer: SVP, Operations C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Kenneth Truitt officer: Chief Medical Officer C/O AQUESTIVE THERAPEUTICS, INC., 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Timothy E Morris director ACELRX PHARMACEUTICALS, INC., 351 GALVESTON DRIVE, REDWOOD CITY CA 94063
Peter E. Boyd officer: SVP-Operations/Value Delivery 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Lori J Braender officer: SVP, General Counsel 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Daniel Barber officer: SVP-Chief Strategy/Dev Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Alexander Mark Schobel director, officer: Chief Innovation/Tech Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Julie Krop director C/O AMAG PHARMACEUTICALS, INC., 1100 WINTER STREET, WALTHAM MA 02451
Marco Taglietti director C/O FOREST LABORATORIES, INC., 909 THIRD AVENUE, NEW YORK NY 10022
Toth A Ernest Jr officer: Interim CFO
John T. Maxwell officer: SVP-Chief Financial Officer 30 TECHNOLOGY DRIVE, WARREN NJ 07059
Keith J Kendall director, officer: President and CEO 30 TECHNOLOGY DRIVE, WARREN NJ 07059
James S Scibetta director C/O BIOENVISION, INC., 345 PARK AVENUE, 41ST. FLOOR, NEW YORK NY 10154

Aquestive Therapeutics (Aquestive Therapeutics) Headlines

From GuruFocus

Aquestive Therapeutics Provides Business Update and Outlines Key 2023 Objectives

By Stock market mentor Stock market mentor 01-06-2023